MA49545A1 - Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci - Google Patents

Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Info

Publication number
MA49545A1
MA49545A1 MA49545A MA49545A MA49545A1 MA 49545 A1 MA49545 A1 MA 49545A1 MA 49545 A MA49545 A MA 49545A MA 49545 A MA49545 A MA 49545A MA 49545 A1 MA49545 A1 MA 49545A1
Authority
MA
Morocco
Prior art keywords
long
composition
glucagon derivative
acting conjugate
glucagon
Prior art date
Application number
MA49545A
Other languages
English (en)
Other versions
MA49545B1 (fr
Inventor
Sung Youb Jung
In Young Choi
Jung Kuk Kim
Young Jin Park
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA49545A1 publication Critical patent/MA49545A1/fr
Publication of MA49545B1 publication Critical patent/MA49545B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un dérivé de glucagon, un conjugué de glucagon à action prolongée du dérivé de glucagon, une utilisation de ceux-ci.
MA49545A 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci MA49545B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150093265 2015-06-30
PCT/KR2016/006984 WO2017003191A1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Publications (2)

Publication Number Publication Date
MA49545A1 true MA49545A1 (fr) 2021-09-30
MA49545B1 MA49545B1 (fr) 2022-03-31

Family

ID=57608802

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41887A MA41887B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
MA49545A MA49545B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41887A MA41887B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Country Status (32)

Country Link
US (3) US10696725B2 (fr)
EP (2) EP3322437B1 (fr)
JP (3) JP6882210B2 (fr)
KR (2) KR102005456B1 (fr)
CN (1) CN108025041A (fr)
AR (1) AR105485A1 (fr)
AU (2) AU2016287209B2 (fr)
BR (1) BR112017028517A2 (fr)
CA (1) CA2991107A1 (fr)
CL (5) CL2017003402A1 (fr)
CO (1) CO2018000303A2 (fr)
CR (1) CR20180034A (fr)
DK (1) DK3322437T3 (fr)
DO (1) DOP2017000318A (fr)
EA (1) EA201890058A1 (fr)
EC (1) ECSP18003879A (fr)
ES (1) ES2973017T3 (fr)
FI (1) FI3322437T3 (fr)
HK (1) HK1248129A1 (fr)
IL (2) IL256619B (fr)
MA (2) MA41887B1 (fr)
MX (1) MX2017016845A (fr)
NZ (1) NZ739250A (fr)
PE (2) PE20180449A1 (fr)
PH (1) PH12017502393A1 (fr)
PL (1) PL3322437T3 (fr)
PT (1) PT3322437T (fr)
TN (1) TN2017000555A1 (fr)
TW (1) TWI713541B (fr)
UA (1) UA127445C2 (fr)
UY (1) UY36759A (fr)
WO (1) WO2017003191A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
WO2016108586A1 (fr) * 2014-12-30 2016-07-07 한미약품 주식회사 Dérivé du glucagon à stabilité améliorée
PE20180449A1 (es) 2015-06-30 2018-03-05 Hanmi Pharm Ind Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
HRP20220995T1 (hr) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore
TN2018000452A1 (en) * 2016-06-29 2020-06-15 Hanmi Pharm Ind Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP3578204A4 (fr) * 2017-02-03 2021-01-06 Hanmi Pharm. Co., Ltd. Conjugué de substance bioactive ayant une durabilité améliorée et son utilisation
WO2018147641A1 (fr) 2017-02-07 2018-08-16 한미약품 주식회사 Composé lieur polymère non peptidique, conjugué comprenant ledit composé lieur, et procédés de préparation desdits composé lieur et conjugué
WO2019066603A1 (fr) * 2017-09-29 2019-04-04 한미약품 주식회사 Conjugué de protéine persistant à efficacité améliorée
WO2020017919A1 (fr) * 2018-07-19 2020-01-23 한미정밀화학주식회사 Nouvel intermédiaire utilisé pour un polypeptide physiologiquement actif et son procédé de préparation
JP2021530533A (ja) * 2018-07-19 2021-11-11 ディーアンドディー ファーマテック インコーポレイテッド ポリペプチドを含む医薬組成物
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
MX2021003830A (es) * 2018-10-04 2021-09-30 Hanmi Pharm Ind Co Ltd Uso terapéutico del glucagón y combinación que incluye el mismo.
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
JP2022514835A (ja) 2018-12-21 2022-02-16 ハンミ ファーマシューティカル カンパニー リミテッド インスリン及びグルカゴンを含む薬学組成物
PL3936142T3 (pl) * 2019-06-28 2024-05-06 Hanmi Pharm. Co., Ltd. Potrójny agonista wykazujący aktywność względem wszystkich pośród receptorów glukagonu, glp-1 oraz gip do leczenia chorób wątroby
CN114786706A (zh) * 2019-10-04 2022-07-22 韩美药品株式会社 胰高血糖素、包含glp-1受体和gip受体双重激动剂的组合物、及其治疗用途
CN110845601B (zh) * 2019-10-12 2021-01-19 广东药科大学 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
JP2023514992A (ja) * 2020-02-21 2023-04-12 スピットファイア ファーマ エルエルシー Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法
CA3179603A1 (fr) * 2020-05-22 2021-11-25 Hanmi Pharm. Co., Ltd. Formulation liquide d'un conjugue a action prolongee d'un derive du glucagon
KR20220009354A (ko) * 2020-07-15 2022-01-24 한미약품 주식회사 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도
JP2023538236A (ja) * 2020-08-14 2023-09-07 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物
JP2024512895A (ja) * 2021-04-09 2024-03-21 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体を含む慢性腎臓疾患予防又は治療用薬学組成物
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
MXPA05009940A (es) 2003-03-19 2005-12-05 Lilly Co Eli Compuestos de glp-1 de enlace de glicol polietilenico.
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
WO2008152403A1 (fr) 2007-06-15 2008-12-18 Zealand Pharma A/S Analogues du glucagon
DK2172479T3 (en) 2007-06-19 2016-12-19 Glytech Inc GLP-1 peptide having the sugar chain attached thereto
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
CA2713348C (fr) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Promedicaments peptidiques a base d'esters
JP6108659B2 (ja) 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
CN102088989B (zh) 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2010096052A1 (fr) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
MX2011013625A (es) * 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
MX342409B (es) 2010-01-20 2016-09-28 Zealand Pharma As Tratamiento de enfermedades cardiacas.
CA2792663A1 (fr) * 2010-03-26 2011-09-29 Novo Nordisk A/S Nouveaux analogues du glucagon
WO2011143208A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille du glucagon manifestant une activité de récepteur couplé à une protéine g
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012088116A2 (fr) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Analogues du glucagon présentant une activité de récepteur de gip
WO2012150503A2 (fr) 2011-05-03 2012-11-08 Zealand Pharma A/S Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
JP6284471B2 (ja) 2011-05-18 2018-02-28 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチドの調合薬
EP3434687B1 (fr) 2011-06-10 2021-03-10 Hanmi Science Co., Ltd. Dérivés inédits d'oxyntomoduline et composition pharmaceutique destinée au traitement de l'obésité en contenant
TR201901402T4 (tr) 2011-06-17 2019-02-21 Hanmi Science Co Ltd Oksintomodulin ve bir immünoglobulin fragmanı içeren bir konjugat ve onun kullanımı.
JP6396211B2 (ja) 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
WO2013120022A2 (fr) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Traitement de l'hypoglycémie
EP2851429B1 (fr) 2012-05-18 2019-07-24 Adda Biotech Inc. Protéine et conjugué protéique pour le traitement du diabète et applications associées
CA2877127A1 (fr) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogues du glucagon presentant une activite sur le recepteur du gip
JP6311708B2 (ja) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
PH12018501454A1 (en) * 2012-11-06 2020-02-17 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglubin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
CA3157899A1 (fr) 2012-11-20 2014-05-30 Mederis Diabetes, Llc Agents pharmaceutiques peptidiques ameliores
CN117903257A (zh) 2012-11-20 2024-04-19 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
CN104870009B (zh) 2012-12-21 2021-05-18 赛诺菲 官能化的毒蜥外泌肽-4衍生物
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
WO2015022420A1 (fr) 2013-08-16 2015-02-19 Medimmune Limited Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
EP3206710B1 (fr) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Conjugués d'insuline-incrétines
WO2016077806A1 (fr) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Protéines de fusion ayant des doubles activités agonistes de récepteur
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016108586A1 (fr) 2014-12-30 2016-07-07 한미약품 주식회사 Dérivé du glucagon à stabilité améliorée
PE20180449A1 (es) 2015-06-30 2018-03-05 Hanmi Pharm Ind Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
US20170004368A1 (en) 2015-07-05 2017-01-05 Neteera Technologies Ltd. System and method for biometric detection based on sweat ducts
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
KR20170065016A (ko) 2015-12-02 2017-06-12 한미약품 주식회사 지방산 유도체를 이용한 단백질 결합체 및 이의 제조방법
HRP20220995T1 (hr) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore

Also Published As

Publication number Publication date
DK3322437T3 (da) 2024-03-25
DOP2017000318A (es) 2018-04-30
WO2017003191A1 (fr) 2017-01-05
MX2017016845A (es) 2018-08-01
JP2021102618A (ja) 2021-07-15
ECSP18003879A (es) 2018-03-31
FI3322437T3 (fi) 2024-02-20
MA41887A1 (fr) 2018-12-31
US10696725B2 (en) 2020-06-30
CL2023001909A1 (es) 2023-11-17
AU2016287209A1 (en) 2018-02-15
PE20180449A1 (es) 2018-03-05
JP2023062043A (ja) 2023-05-02
MA41887B1 (fr) 2020-05-29
TWI713541B (zh) 2020-12-21
CN108025041A (zh) 2018-05-11
US20180186853A1 (en) 2018-07-05
MA49545B1 (fr) 2022-03-31
AU2016287209B2 (en) 2023-03-02
CA2991107A1 (fr) 2017-01-05
KR102005456B1 (ko) 2019-07-30
ES2973017T3 (es) 2024-06-18
US20200223897A1 (en) 2020-07-16
UY36759A (es) 2017-01-31
EP4324519A2 (fr) 2024-02-21
EP3322437A1 (fr) 2018-05-23
US11667688B2 (en) 2023-06-06
EP3322437B1 (fr) 2024-01-17
CL2023001910A1 (es) 2023-11-17
CR20180034A (es) 2018-04-16
JP2018526333A (ja) 2018-09-13
JP6882210B2 (ja) 2021-06-02
TW201713681A (zh) 2017-04-16
CO2018000303A2 (es) 2018-07-10
PE20240215A1 (es) 2024-02-16
KR20170003466A (ko) 2017-01-09
CL2017003402A1 (es) 2018-04-20
PT3322437T (pt) 2024-03-20
BR112017028517A2 (pt) 2018-08-28
KR102395855B1 (ko) 2022-05-10
AU2023201118A1 (en) 2023-04-20
IL256619A (en) 2018-04-30
HK1248129A1 (zh) 2018-10-12
IL256619B (en) 2022-04-01
CL2023001911A1 (es) 2023-11-17
CL2023000198A1 (es) 2023-06-30
EA201890058A1 (ru) 2018-07-31
PL3322437T3 (pl) 2024-05-20
EP3322437A4 (fr) 2019-10-09
UA127445C2 (uk) 2023-08-30
NZ739250A (en) 2024-02-23
IL291291B2 (en) 2023-06-01
AR105485A1 (es) 2017-10-11
US20220127325A1 (en) 2022-04-28
TN2017000555A1 (en) 2019-04-12
KR20190092343A (ko) 2019-08-07
US11261227B2 (en) 2022-03-01
IL291291A (en) 2022-05-01
PH12017502393A1 (en) 2018-06-25

Similar Documents

Publication Publication Date Title
MA41887B1 (fr) Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
CR20160419A (es) Nuevos compuestos biciclicos
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201992177A1 (ru) Композиции на основе нирапариба
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
MA45857A (fr) Composés et compositions, et utilisations associées
MA45795A (fr) Composés et compositions, et utilisations associées
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
CL2019002115S1 (es) Estructura de detonador.
FR3056590B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
ES1241151Y (es) Multi-colmena.
CL2018003015S1 (es) Cápsula.
CL2018003014S1 (es) Cápsula.
IT201700080501A1 (it) Riduttore.
MA42889B2 (fr) Triple activateur activant le récepteur du glucagon, du glp-1 et du gip
EA201792492A1 (ru) Aml-антигены и их применение
IT201700023838A1 (it) Struttura di schienale.
FR3056586B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
FR3056585B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
FR3056589B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
FR3056587B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane